{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:55:58Z","timestamp":1789232158952,"version":"build-2803163510"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>OnabotulinumtoxinA safety and efficacy are well established for upper facial lines (UFL), including forehead lines (FHL), glabellar lines (GL), and crow's feet lines (CFL).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To investigate the association of onabotulinumtoxinA efficacy with patient-reported psychological impacts and satisfaction in UFL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MATERIALS AND METHODS<\/jats:title>\n            <jats:p>A pooled analysis of data from 4 pivotal Phase 3 trials (onabotulinumtoxinA vs placebo in FHL \u00b1 GL, FHL + GL \u00b1 CFL, CFL, and CFL + GL for \u2264180 days) evaluated investigator-assessed \u22651-grade severity improvement on the Allergan Facial Wrinkle Scale at Day 30 (responders). Facial Line Outcomes (FLO-11) Questionnaire, Facial Line Satisfaction Questionnaire (FLSQ), and Subject Assessment of Satisfaction of Appearance (SASA) were used to evaluate responder appearance-related psychological impacts and satisfaction.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>OnabotulinumtoxinA patients, by primary study focus (FHL, GL, or CFL), totaled 921, 921, and 833, respectively; 786 patients received placebo. Most patients were female, White, and aged 45 to 50 years (median). Through 150 days, &gt;42% FHL, &gt;43% GL, and \u226532% CFL patients were onabotulinumtoxinA responders. Responders reported improvements in appearance-related psychological impacts (FLO-11) and high satisfaction (FLSQ and SASA), sustained through \u2265150 days.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>A \u22651-grade improvement with onabotulinumtoxinA is a clinically meaningful outcome in UFL, associated with long-lasting improved patient-reported psychological impacts and high satisfaction.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000003585","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T09:02:06Z","timestamp":1667811726000},"page":"1191-1197","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["High Patient Satisfaction for up to 6 Months With OnabotulinumtoxinA Treatment for Upper Facial Lines"],"prefix":"10.1097","volume":"48","author":[{"given":"Joel L.","family":"Cohen","sequence":"first","affiliation":[{"name":"AboutSkin Dermatology and DermSurgery, PC, Greenwood Village, Colorado;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Fagien","sequence":"additional","affiliation":[{"name":"Private Practice, Boca Raton, Florida;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Ogilvie","sequence":"additional","affiliation":[{"name":"AboutSkin Dermatology and DermSurgery, PC, Greenwood Village, Colorado;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koenraad","family":"De Boulle","sequence":"additional","affiliation":[{"name":"AboutSkin Dermatology and DermSurgery, PC, Greenwood Village, Colorado;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Carruthers","sequence":"additional","affiliation":[{"name":"AboutSkin Dermatology and DermSurgery, PC, Greenwood Village, Colorado;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue Ellen","family":"Cox","sequence":"additional","affiliation":[{"name":"AboutSkin Dermatology and DermSurgery, PC, Greenwood Village, Colorado;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Kelly","sequence":"additional","affiliation":[{"name":"Peloton Advantage, LLC, an OPEN Health company, Parsippany, New Jersey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia K.","family":"Garcia","sequence":"additional","affiliation":[{"name":"Allergan Aesthetics, an AbbVie Company, Irvine, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Sangha","sequence":"additional","affiliation":[{"name":"Allergan Aesthetics, an AbbVie Company, Irvine, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,5]]},"reference":[{"key":"R1-20250731","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/DSS.0000000000000876","article-title":"Facial treatment preferences among aesthetically oriented men","volume":"42","author":"Jagdeo","year":"2016","journal-title":"Dermatol Surg"},{"key":"R2-20250731","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1097\/DSS.0000000000000293","article-title":"Facial treatment preferences in aesthetically aware women","volume":"41","author":"Narurkar","year":"2015","journal-title":"Dermatol Surg"},{"key":"R3-20250731","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00042728-200305000-00003","article-title":"Social implications of hyperfunctional facial lines","volume":"29","author":"Finn","year":"2003","journal-title":"Dermatol Surg"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/01.iio.0000167237.49396.7b","article-title":"Social implications of hyperdynamic facial lines and patient satisfaction outcomes","volume":"45","author":"Cox","year":"2005","journal-title":"Int Ophthalmol Clin"},{"key":"R5-20250731","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.det.2005.05.012","article-title":"Psychosocial aspects of aging skin","volume":"23","author":"Gupta","year":"2005","journal-title":"Dermatol Clin"},{"key":"R7-20250731","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.fsc.2009.11.014","article-title":"Botox facial slimming\/facial sculpting: the role of botulinum toxin-A in the treatment of hypertrophic masseteric muscle and parotid enlargement to narrow the lower facial width","volume":"18","author":"Wu","year":"2010","journal-title":"Facial Plast Surg Clin North Am"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1067\/mjd.2002.121356","article-title":"A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines","volume":"46","author":"Carruthers","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R10-20250731","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/01.PRS.0000076504.79727.62","article-title":"Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines","volume":"112","author":"Carruthers","year":"2003","journal-title":"Plast Reconstr Surg"},{"key":"R11-20250731","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/DSS.0000000000000128","article-title":"Efficacy and safety of onabotulinumtoxinA for the treatment of crow's feet lines: a multicenter, randomized, controlled trial","volume":"40","author":"Carruthers","year":"2014","journal-title":"Dermatol Surg"},{"key":"R12-20250731","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/DSS.0000000000000220","article-title":"Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial","volume":"41","author":"Moers-Carpi","year":"2015","journal-title":"Dermatol Surg"},{"key":"R13-20250731","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1097\/DSS.0000000000001414","article-title":"Forehead line treatment with onabotulinumtoxinA in subjects with forehead and glabellar facial rhytids: a phase 3 study","volume":"43","author":"Fagien","year":"2017","journal-title":"Dermatol Surg"},{"key":"R14-20250731","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1097\/DSS.0000000000001612","article-title":"Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines","volume":"44","author":"De Boulle","year":"2018","journal-title":"Dermatol Surg"},{"key":"R15-20250731","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/DSS.0000000000001883","article-title":"OnabotulinumtoxinA for simultaneous treatment of upper facial lines: subject-reported satisfaction and impact from a phase 3 study","volume":"46","author":"Rivkin","year":"2020","journal-title":"Dermatol Surg"},{"key":"R16-20250731","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/DSS.0000000000002153","article-title":"Pooled subject-reported outcomes from 2 phase 3 studies of onabotulinumtoxinA for simultaneous treatment of forehead and glabellar lines","volume":"46","author":"Ogilvie","year":"2020","journal-title":"Dermatol Surg"},{"key":"R17-20250731","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/jocd.12117","article-title":"The impact of upper facial lines and psychological impact of crow's feet lines: content validation of the Facial Line Outcomes (FLO-11) Questionnaire","volume":"13","author":"Yaworsky","year":"2014","journal-title":"J Cosmet Dermatol"},{"key":"R18-20250731","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/jocd.12166","article-title":"Development and validation of a novel patient-reported treatment satisfaction measure for hyperfunctional facial lines: Facial Line Satisfaction Questionnaire","volume":"14","author":"Pompilus","year":"2015","journal-title":"J Cosmet Dermatol"},{"key":"R19-20250731","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1097\/DSS.0000000000001926","article-title":"Clinical assessment of 2 licensed abobotulinumtoxinA injection volumes for the treatment of glabellar lines","volume":"45","author":"Kaufman","year":"2019","journal-title":"Dermatol Surg"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000003585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:09:12Z","timestamp":1753999752000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000003585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,5]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000003585","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,5]]}}}